Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retinitis Pigmentosa
Biotech
J&J gene therapy fails ph. 3 rare eye disease trial
The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa.
Darren Incorvaia
May 5, 2025 11:33am
NIH creates eye drops that protect mice from vision loss
Mar 25, 2025 3:10pm
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
ProQR, Théa ink new pact for eye assets after old one collapsed
Dec 8, 2023 11:01am
Nanoscope's gene therapy boosts vision function in phase 2 test
Mar 30, 2023 11:04am
J&J links gene therapy to improved vision in early-phase trial
Oct 3, 2022 8:00am
